REG - Yourgene Health PLC - Notice of AGM & Change of Registered Address

Yourgene HealthAnnouncement

25/08/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220825:nRSY1343Xa&default-theme=true

RNS Number : 1343X  Yourgene Health PLC  25 August 2022

Yourgene Health plc

("Yourgene", the "Company" or the "Group")

 

Notice of AGM, Change of Registered Address and

Investor Presentation

 

Manchester, UK - 25 August 2022: Yourgene (AIM: YGEN), the international
molecular diagnostics group, announces that the Notice of Annual General
Meeting ("AGM") and Form of Proxy will shortly be available on the Company's
website
at: www.yourgene-health.com/investors/key-documents/shareholder-communications
(http://www.yourgene-health.com/investors/key-documents/shareholder-communications)
 and are being posted to those shareholders who have opted out of electronic
communications.

 

The majority of Yourgene shareholders receive electronic communications as
part of the Company's ESG programme. Yourgene is writing to all remaining
shareholders to ask them to do the same to reduce paper usage and support the
Company on its ESG initiatives.

 

Change of registered office

Yourgene also announces that the Company's registered office address has
changed to: Skelton House, Lloyd Street North, Manchester Science Park,
Manchester M15 6SH with immediate effect.

 

Notice of AGM and Investor presentation

The Company's AGM will be held at 2:00pm (BST) on Tuesday 27 September 2022,
and will be held as a hybrid meeting  electronically, via the Investor Meet
Company platform ("IMC") and physically, at the Company's new offices Skelton
House, Lloyd Street North, Manchester Science Park, Manchester M15 6SH.

 

The Company's CEO, Lyn Rees, will also provide shareholders with a short
presentation after the formal business of the AGM concludes and there will be
an opportunity for investors to ask questions. Investors can sign up to IMC
for free and add to meet Yourgene Health plc via:

 

https://www.investormeetcompany.com/yourgene-health-plc/register-investor
(https://www.investormeetcompany.com/yourgene-health-plc/register-investor)

 

Shareholders taking part via the IMC platform will not be able to speak or
vote on the AGM resolutions. Shareholders are therefore strongly encouraged to
exercise their voting rights by completing and submitting a Form of Proxy. It
is highly recommended that Shareholders submit their Form of Proxy as early as
possible to ensure that their votes are counted at the AGM. Shareholders are
strongly encouraged to appoint the Chairman as your proxy to ensure that each
Shareholder's vote will be counted in the event of restrictions on
shareholders and proxies attending the AGM in person.

 

If you wish to submit a proxy vote for this meeting, please submit your vote
online at www.signalshares.com. For your vote to be valid please ensure that
it is received by no later than 2:00pm (BST) on Friday 23 September 2022.
Alternatively, should you wish to vote via the CREST system, please see the
instructions in the Notice of Meeting.

 

If you wish to attend the AGM in your capacity as a shareholder, please bring
proof of shareholding or if shares are held through a nominee account, a
letter of representation, to facilitate your entry to the Meeting. Any
shareholder wishing to attend in person must register in advance by contacting
the Company at yourgene@walbrookpr.com (mailto:yourgene@walbrookpr.com) .

 

Open Day

As previously announced on 16 August 2022, the Company is hosting an Open Day,
immediately after the AGM, at its new facilities at Manchester Science Park,
on Tuesday 27 September 2022 from 3:00pm to 6:00pm (BST), welcoming
shareholders, analysts and other interested stakeholders.

 

All Open Day attendees must register through Walbrook PR to reserve a space.
For more information and to register, please email yourgene@walbrookpr.com
(mailto:yourgene@walbrookpr.com)  or telephone Walbrook PR on +44 (0)20 7933
8780.

 

 Yourgene Health plc                                Tel: +44 (0)161 669 8122

 Lyn Rees, Chief Executive Officer                  investors@yourgene-health.com (mailto:investors@yourgene-health.com)
 Barry Hextall, Chief Financial Officer
 Joanne Cross, Director of Marketing

 Cairn Financial Advisers LLP (NOMAD)               Tel: +44 (0)20 7213 0880
 Liam Murray / James Caithie / Ludovico Lazzaretti

 Singer Capital Markets (Corporate Broker)          Tel: +44 (0)20 7496 3000
 Aubrey Powell / Tom Salvesen / George Tzimas

 Walbrook PR Ltd (Media and Investor Relations)     Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
                                                    (mailto:yourgene@walbrookpr.com)
 Lianne Applegarth / Alice Woodings                 Mob: 07584 391 303 / 07407 804 654

 

About Yourgene Health

 

Yourgene Health is an international molecular diagnostics group which develops
integrated genomic technologies and services enabling precision medicine. The
group works in partnership with global leaders in DNA technology to advance
diagnostic science.

 

Yourgene primarily develops, manufactures, and commercialises simple and
accurate molecular diagnostic solutions, for reproductive health, precision
medicine and now infectious diseases. The Group's flagship products include
non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests,
and a recent extension into the oncology space with DPYD genotyping.

 

The Yourgene Genomic Services team works with healthcare professionals,
researchers and pharmaceutical organisations to support and accelerate
scientific advances in genomic medicine. The division's specialist services
guide decisions about abnormalities, hereditary risk and treatment in addition
to providing novel insights in research and discovery. Accredited clinical
services are provided in Oncology and Reproductive Health within the UK and
worldwide. The team of scientific experts offer consultative services to help
guide partners in selecting the right technology and approach for their
applications.

 

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation
technology company based in Vancouver, Canada, enabling the Company to extend
its offering and IP portfolio in the DNA sample preparation sector. The
acquisition increased Yourgene's geographical penetration into the US and
Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei,
Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM
market under the ticker "YGEN". For more information visit
www.yourgene-health.com (http://www.yourgene-health.com/) and follow us on
twitter @Yourgene_Health.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSEEFMLEESEEA